Abstract:Primary immune thrombocytopenia (ITP) has been traditionally thought as an antibody-mediated autoimmune disease involving platelet destruction by macrophages in the reticuloendothelia system. More recently it has become obvious that ITP is a more complex disorder in which T cell mediated immunity plays important roles in platelet destruction. Antiplatelet autoantibody production is under the control of platelet-specific helper T-cells, and loss of tolerance to self antigen by T cells is the critical step of the immune dysregulation in ITP. Dendritic cells (DCs) from ITP patients showed enhanced capacity in stimulating autologous T-cell proliferation in the presence of autologous/allogeneic platelets [1], and ITP patients’ T cells had elevated IL-2 secretion ability compared with controls [2,3], suggesting increased antiplaltelet T-cell reactivity in ITP. The epitopes that recognize platelet glycoprotein (GP) IIIa on T helper (Th) cells has been determined and mapped by several groups [4,5], thus sheding new lights on the “therapeutic vaccination” approach to reinstate tolerance in ITP. Autoreactive T-cell reactivity against platelet antigen in active ITP patients has been observed at polyclonal as well as oligoclonal levels [6,7]. Our group has demonstrated that blocking the B7-CD28 interaction with CTLA4-Ig/CsA could induce platelet GP-specific T-cell anergy, which could exert suppressive effect on GP-reactive T cells via inducing tolerogenic dendritic cells (DCs) [8,9]. It has been well established that apoptotic genes, such as Fas, A20, Bax, Calpastatin, IL2RB, were expressed aberrantly in patients with active ITP [10,11], leading to autoreactive T cells resistant to activation induced cell death (AICD), which could in turn support the expansion of self-reactive T-cell clones. A loss of resistant to AICD might be an important mechanism for the achievement of remission in ITP. Previous studies have revealed that dexamethasone could suppress T-cell proliferation and induce apoptosis of T-cells in ITP [11,12]. In addition, our group has demonstrated that a novel BAFF blocking reagent, BR3-Fc, could restore the apoptosis of both B and T cells [13]. Th polarization in ITP has been attributed to increased Th1 [2,14], and Th17 cells [15] or reduced number or function of CD4+CD25+Foxp3+ T-regulatory cells (Tregs) [16,17]. A parallel body of aberrant cytokine patterns, such as the elevated ratio of interleukin (IL) -18/IL-18 binding protein (BP) [18,19], the increased expression of B cell activating factor (BAFF) has been reported in active ITP patients [20,21]. High-dose dexamthasone (HD-DXM) could not only restore Th1/Th2 [14] or IL-18/IL-18BP balance [19], but also increase the number of Tregs [16], and inhibit the expression of BAFF [12]. Besides HD-DXM, multiple agents, such as rituximab [22], intravenous immunoglobulin (IVIg) [23], romiplostim, eltrombopag [24] as well as indirubin [25], could increase the number or restore the function of Tregs in ITP. Our recently study showed that GP-specific induced Tregs could be successfully generated de novo from nonregulatory CD4+CD25-CD45RA+ cells and could mediate both antigen-specific and linked suppression of proliferating antiplatelet CD4+ Th cells in vitro, and further research revealed that the de novo expanded Tregs mediated their suppressive effects on T cells via actually modulating the T-cell stimulatory capacity of DCs [26], thus providing a clue to the potential of producing antigen-specific Tregs from the patients in vitro for the purpose of antigen-targeted cellular immunotherapy. In conclusion, induction of T-cell tolerance may provide a useful strategy for the management of ITP.

Pulsed High-dose Dexamethasone Improves Interleukin 10 Secretion by CD5 + B Cells in Patients with Primary Immune Thrombocytopenia

Effects of High-Dose Dexamethasone on Regulating Interleukin-22 Production and Correcting Th1 and Th22 Polarization in Immune Thrombocytopenia

High-dose Dexamethasone Modulates Serum Cytokine Profile in Patients with Primary Immune Thrombocytopenia.

Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia.

Changes in Follicular Helper T Cells in Idiopathic Thrombocytopenic Purpura Patients.

[Impaired Interleukin-10 Secretion by CD5(+) B Cells in Patients with Primary Immune Thrombocytopenia].

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia

Efficacy of High-dose Dexamethasone in Combination with Recombinant Human Interleukin-11 in Adult Patients with Severe Primary Immune Thrombocytopenia

High-dose Dexamethasone Corrects Impaired Myeloid-Derived Suppressor Cell Function Via Ets1 in Immune Thrombocytopenia.

High-dose Dexamethasone Shifts the Balance of Stimulatory and Inhibitory Fcγ Receptors on Monocytes in Patients with Primary Immune Thrombocytopenia

Alteration and Biological Significance of Peripheral Dendritic Cells in Patients with Chronic Idiopathic Thrombocytopenic Purpura

The Abnormal Function of CD39+ Regulatory T Cells Could Be Corrected by High-Dose Dexamethasone in Patients with Primary Immune Thrombocytopenia

Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia

Functional Plasticity in CD4+ CD25+ CD127- Treg Population in Primary Immune Thrombocytopenia

High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial

Aberrant Frequency of IL-10-producing B Cells and Its Association with Treg/Th17 in Adult Primary Immune Thrombocytopenia Patients.

[Curative Efficacy of Rituximab for ITP Patients with Different Sensitivity to Hormone].

Restoration of T Cell Tolerance in Primary ITP

Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4 + T effector cells in newly diagnosed adult immune thrombocytopenia patients

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

[Efficacy and Safety of Low-Dose Rituximab Combined with Different Dosage of Glucocorticoids for Immune Thrombocytopenia].